Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Efficacy and safety of zanubrutinib-containing regimens in patients with newly diagnosed Mantle Cell Lymphoma: Interim results from a Phase II investigator-initiated study

Blood (2025) 146 (Supplement 1): 1823.

https://doi.org/10.1182/blood-2025-1823

Published: 2025

Journal Articles

Hetrombopag for patients with persistent primary immune thrombocytopenia: A post-hoc analysis of a multicenter, randomized phase Ⅲ Trial

Blood (2025) 146 (Supplement 1): 4812.

https://doi.org/10.1182/blood-2025-4812

Published: 2025

Journal Articles

Long-term treatment continuation of gecacitinib in myelofibrosis patients after ruxolitinib failure

Blood (2025) 146 (Supplement 1): 5584.

https://doi.org/10.1182/blood-2025-5584

Published: 2025

Journal Articles

Indirect treatment comparison of novel JAK2 Inhibitor OB756 versus ruxolitinib in polycythaemia vera with splenomegaly

Jian Huang, Bingbing Wen, Tiejun Gong, Hu Zhou, Qingchi Liu, Lihong Shou, Feng Zhang, Cuicui Wu, Wei Yang, Lidong Zhao, Lili Chen, Jian Lu, Yile Zhou, Yi Zhang, Jie Jin

Blood (2025) 146 (Supplement 1): 7351.

https://doi.org/10.1182/blood-2025-7351

Published: 2025

Journal Articles

Efficacy and safety results of linperlisib in adult patients with primary immune thrombocytopenia (ITP)

Hu Zhou, Bingjie Ding, Fengdi Wang, Xuewen Song, Mengjuan Li, Junxia Hu, Ao Xie

Blood (2025) 146 (Supplement 1): 845.

https://doi.org/10.1182/blood-2025-845

Published: 2025

Journal Articles

Phase 3 ESLIM-01 study: Final analysis of efficacy and safety of long-term treatment with sovleplenib in adults with chronic primary immune thrombocytopenia

Blood (2025) 146 (Supplement 1): 843.

https://doi.org/10.1182/blood-2025-843

Published: 2025

Journal Articles

XPO1 inhibitor WJ01024 monotherapy or in combination with ruxolitinib in myelofibrosis

Hu Zhou, Xuewen Song, Mengjuan Li, Bingjie Ding, Yirong Zhao, Baojie Ma, Lihui Qian, Yuli Xie

Blood (2025) 146 (Supplement 1): 3792.

https://doi.org/10.1182/blood-2025-3792

Published: 2025

Journal Articles

Real-world study on thrombopoietin receptor agonists combined with rituximab in the treatment of Relapsed/Refractory primary immune thrombocytopenia

Hong Tian, Xuewen Song, Ruinan Lu, LiLi Ji, Yun Li, Haiju He, ziqiang Yu, Hu Zhou, Jie Yin

Blood (2025) 146 (Supplement 1): 3048.

https://doi.org/10.1182/blood-2025-3048

Published: 2025

Journal Articles

ROCK2 inhibition attenuates CTL-mediated platelet destruction by suppressing IL-6/STAT3-driven glycolysis in primary immune thrombocytopenia

Juanjuan Song, Xinguang Liu, Hu Zhou

Blood (2025) 146 (Supplement 1): 3012.

https://doi.org/10.1182/blood-2025-3012

Published: 2025

Journal Articles

BCL-2 inhibitor TQB3909 combined with JAK inhibitors in patients with intermediate- or high-risk myelofibrosis: A two-cohort, open-label, Phase ib/II, multicenter study

Jian Huang, Tian Zeng, Xiudi Yang, Xingli Zhao, Guangxun Gao, Hu Zhou, Hongyan Tong

Blood (2025) 146 (Supplement 1): 2034.

https://doi.org/10.1182/blood-2025-2034

Published: 2025

Journal Articles

Ferritin change and predictors of anemia response in ruxolitinib-intolerant myelofibrosis patients treated with gecacitinib

Yi Zhang, Hu Zhou, Zhijian Xiao, Minghui Duan, Sujun Gao, Guangsheng He, Hongmei Jing, Junmin Li, Liangming Ma, Huanling Zhu, Chunkang Chang, Xin Du, Mei Hong, Xin Li, Qingchi Liu, Wei WANG, Na Xu, Haiping Yang, Jie Jin

Blood (2025) 146 (Supplement 1): 2029.

https://doi.org/10.1182/blood-2025-2029

Published: 2025

Journal Articles

Efficacy and safety of gecacitinib in thrombocytopenic myelofibrosis patients

Blood (2025) 146 (Supplement 1): 2028.

https://doi.org/10.1182/blood-2025-2028

Published: 2025

Journal Articles

Safety and efficacy of the JAK/rock inhibitor rovadicitinib in combination with the bromodomain and extra-terminal inhibitor TQB3617 in patients with myelofibrosis: A phase ib/II study

Chunkang Chang, Xuliang Shen, Hu Zhou, Min Zhang, Zongjiu Jiao, Sujun Gao, Zhenya Hong, Zhihua Zhang, Jianping Hao, Tiejun Gong, Hongmei Ma, Xue Lan Zuo, Guohua Yang, Junying Wu, Luxi Song, Duoer Wu, Dawei Ding, Shanli Lao, Ding Yu

Blood (2025) 146 (Supplement 1): 481.

https://doi.org/10.1182/blood-2025-481

Published: 2025

Journal Articles

A dose-escalation and safety study of CID-103 followed by a randomized, open-label, parallel-arm multi-dose study evaluating the efficacy and tolerability of CID-103 in adults with persistent or chronic immune thrombocytopenia

Chen Yunfei, ZePing Zhou, Hu Zhou, Ruibin Huang, Zhenyu Yan, Jun Peng, Ming Hou, James Bussel, Alexander Zukiwski, Junping Chen, Lei Zhang

Blood (2025) 146 (Supplement 1): 3035.

https://doi.org/10.1182/blood-2025-3035

Published: 2025

Journal Articles

Remarkable Molecular Response in Patients with Polycythemia Vera Treated with Ropeginterferon Alfa-2b

Blood (2024) 144 (Supplement 1): 4562.

https://doi.org/10.1182/blood-2024-203148

Published: 2024

Journal Articles

Efficacy and Safety of an Engineered, Liver-Tropic Adeno-Associated Virus Vector Expressing Factor IX Padua Administered with Prophylactic Glucocorticoids in Patients with Hemophilia B: A Multi-Center, Single-Arm, Phase 3 Trial

Feng Xue, Mankai Ju, Tienan Zhu, ZePing Zhou, Jing Sun, Linhua Yang, Zhenyu Yan, Hu Zhou, Xin Du, Changcheng Zheng, Xia Wu, Xiao Xiao, Renchi Yang, Lei Zhang

Blood (2024) 144 (Supplement 1): 3582.

https://doi.org/10.1182/blood-2024-204715

Published: 2024

Journal Articles

A Specific Coagulation Factor X Activator for on-Demand Treatment in Hemophilia with Inhibitors

Wei Liu, Hu Zhou, Ruibin Huang, Xin Du, ZePing Zhou, Changcheng Zheng, Shifeng Lou, Xinyue Dai, Renchi Yang, Lei Zhang

Blood (2024) 144 (Supplement 1): 1213.

https://doi.org/10.1182/blood-2024-199149

Published: 2024

Journal Articles

A Novel JAK2 Inhibitor OB756 in Treatment of Janus Kinase Inhibitor-Naive Patients with Myelofibrosis: A Phase 1/2, Open-Label, Multicenter Study

Blood (2024) 144 (Supplement 1): 1808.

https://doi.org/10.1182/blood-2024-212216

Published: 2024

Journal Articles

First in-Class JAK2 Inhibitor OB756 Therapy for Patients with Polycythemia Vera : A Phase 2, Open-Label, Multicenter Study

Jian Huang, Bingbing Wen, Tiejun Gong, Hu Zhou, Lihong Shou, Qingchi Liu, Feng Zhang, Cuicui WU, Wei Yang, Lidong Zhao, Lili Chen, Jian Lu, Yile Zhou, Yi Zhang, Jie Jin

Blood (2024) 144 (Supplement 1): 3180.

https://doi.org/10.1182/blood-2024-210330

Published: 2024

Journal Articles

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Blood (2024) 144 (Supplement 1): 3165.

https://doi.org/10.1182/blood-2024-202790

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Efficacy and safety of zanubrutinib-containing regimens in patients with newly diagnosed Mantle Cell Lymphoma: Interim results from a Phase II investigator-initiated study

Hetrombopag for patients with persistent primary immune thrombocytopenia: A post-hoc analysis of a multicenter, randomized phase Ⅲ Trial

Long-term treatment continuation of gecacitinib in myelofibrosis patients after ruxolitinib failure

Indirect treatment comparison of novel JAK2 Inhibitor OB756 versus ruxolitinib in polycythaemia vera with splenomegaly

Efficacy and safety results of linperlisib in adult patients with primary immune thrombocytopenia (ITP)

Phase 3 ESLIM-01 study: Final analysis of efficacy and safety of long-term treatment with sovleplenib in adults with chronic primary immune thrombocytopenia

XPO1 inhibitor WJ01024 monotherapy or in combination with ruxolitinib in myelofibrosis

Real-world study on thrombopoietin receptor agonists combined with rituximab in the treatment of Relapsed/Refractory primary immune thrombocytopenia

ROCK2 inhibition attenuates CTL-mediated platelet destruction by suppressing IL-6/STAT3-driven glycolysis in primary immune thrombocytopenia

BCL-2 inhibitor TQB3909 combined with JAK inhibitors in patients with intermediate- or high-risk myelofibrosis: A two-cohort, open-label, Phase ib/II, multicenter study

Ferritin change and predictors of anemia response in ruxolitinib-intolerant myelofibrosis patients treated with gecacitinib

Efficacy and safety of gecacitinib in thrombocytopenic myelofibrosis patients

Safety and efficacy of the JAK/rock inhibitor rovadicitinib in combination with the bromodomain and extra-terminal inhibitor TQB3617 in patients with myelofibrosis: A phase ib/II study

A dose-escalation and safety study of CID-103 followed by a randomized, open-label, parallel-arm multi-dose study evaluating the efficacy and tolerability of CID-103 in adults with persistent or chronic immune thrombocytopenia

Remarkable Molecular Response in Patients with Polycythemia Vera Treated with Ropeginterferon Alfa-2b

Efficacy and Safety of an Engineered, Liver-Tropic Adeno-Associated Virus Vector Expressing Factor IX Padua Administered with Prophylactic Glucocorticoids in Patients with Hemophilia B: A Multi-Center, Single-Arm, Phase 3 Trial

A Specific Coagulation Factor X Activator for on-Demand Treatment in Hemophilia with Inhibitors

A Novel JAK2 Inhibitor OB756 in Treatment of Janus Kinase Inhibitor-Naive Patients with Myelofibrosis: A Phase 1/2, Open-Label, Multicenter Study

First in-Class JAK2 Inhibitor OB756 Therapy for Patients with Polycythemia Vera : A Phase 2, Open-Label, Multicenter Study

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only